stars 1 stars 2 stars 3

NeuroSolis, Inc. is an early-stage company located in Madison and organized in the State of Wisconsin. We are developing NSX-0527 for neurological and psychiatric indications. Our goal is to help the 5.2 million Americans afflicted with Alzheimer's Disease and the 2.5 million afflicted with schizophrenia. Our drug candidate, NSX-0527, is the culmination of a two-year program to enhance the properties of MCD-386, a compound which had shown positive results in Phase 1 clinical trials. NeuroSolis is currently seeking investment to fund animal safety pharmacology and toxicity studies to enable filing of an Investigational New Drug (IND) application needed to commence human clinical trials.

NeuroSolis Questions

The NeuroSolis annual revenue was $206000 in 2026.

Alex Kasper is the Co-Founder of NeuroSolis.

1 people are employed at NeuroSolis.

NeuroSolis is based in Madison, Wisconsin.

The NAICS codes for NeuroSolis are [32541, 325, 32, 3254].

The SIC codes for NeuroSolis are [283, 28].

Top NeuroSolis Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users